Industry Research Reports

Part 1

Part 2

Part 3

Part 4

Part 5

Home > Reports > Medical Care > Global LFA-based Cardiac Marker Market Outlook, In‑Depth Analysis & Forecast to 2031

Global LFA-based Cardiac Marker Market Outlook, In‑Depth Analysis & Forecast to 2031

Industry: Medical Care

Published: 2025-08-08

Pages: 142 Pages

Report ld: 4921463

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description

The global LFA-based Cardiac Marker market is projected to grow from US$ 3839 million in 2024 to US$ 5853 million by 2031, at a CAGR of 6.7% (2025-2031), driven by critical product segments and diverse end‑use applications.

LFA-based Cardiac Marker is a cardiac marker test based on lateral flow chromatography technology. Lateral flow chromatography technology is a detection method based on the principle of paper chromatography. It is widely used in the detection of disease biomarkers, especially in line with the World Health Organization's REASSURED principle in clinical testing, that is, reasonable cost, high sensitivity, strong specificity, convenient operation, fast and stable, no need for special equipment, easy promotion, real-time feedback, easy sampling, and environmentally friendly. Cardiac markers refer to proteins or enzymes that are released into the peripheral blood and detected during the course of heart disease. They can reflect changes in the structure or function of the heart. Cardiac marker detection based on lateral flow chromatography technology uses the advantages of lateral flow chromatography technology to quickly, accurately and conveniently detect cardiac markers to meet the clinical needs for immediate detection of heart disease.

LFA-based Cardiac Marker Market Size(US$)

M= millions and B=billions

Market Drivers
Rising Prevalence of Cardiovascular Diseases:
The prevalence of cardiovascular diseases is increasing globally, especially in low- and middle-income countries. This has led to an increase in demand for cardiac marker testing, as cardiac marker testing plays an important role in early diagnosis, risk assessment, and treatment monitoring of heart disease.

Technological Advances and Cost Reductions:
With the advancement of science and technology, the sensitivity and specificity of lateral flow chromatography technology has continued to improve, while the cost of testing has gradually decreased. This has made cardiac marker testing based on lateral flow chromatography technology more popular and acceptable, further driving the development of the market.

Growing Demand for Home Testing:
Home testing (also known as self-testing) allows users to test self-collected samples and obtain results without the assistance of trained medical professionals. This testing method plays an important role in cardiovascular diseases and infectious diseases. With the improvement of consumers' health awareness and the popularity of home testing products, the demand for cardiac marker home testing products based on lateral flow chromatography technology is also increasing.

Support from policies and regulations:
The policy support of governments for medical health and technological innovation has provided a good policy environment for the development of the cardiac marker testing market based on lateral flow chromatography technology. For example, the government may introduce relevant policies to encourage innovation, reduce testing costs, and improve testing accuracy, thereby promoting the development of the market.

Population aging and increased medical needs:
As the global population ages, the elderly population's demand for medical and health services continues to increase. Heart disease is one of the common chronic diseases among the elderly, so the application prospects of cardiac marker detection based on lateral flow chromatography technology in the elderly population are broad.

In summary, the development of the cardiac marker detection market based on lateral flow chromatography technology is driven by a variety of factors, including the increase in the prevalence of cardiovascular diseases, technological advances and cost reductions, the growth of home testing needs, policy and regulatory support, and the aging population and increased medical needs. These factors have jointly promoted the rapid development and widespread application of the market.

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global LFA-based Cardiac Marker market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Report Metric
Details
Report Title
Global LFA-based Cardiac Marker Market Outlook, In‑Depth Analysis & Forecast to 2031
Forecasted Market Size in 2031
US$ 5853 million
CAGR(2025-2031)
6.7%
Market Size Available for Years
2025-2031
Global LFA-based Cardiac Marker Companies Covered
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
Global LFA-based Cardiac Marker Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global LFA-based Cardiac Marker Market, Segment by Type
Troponin
CK-MB
Myoglobin
Others
Global LFA-based Cardiac Marker Market, Segment by Application
Laboratory Testing
Point-of-care Testing
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Defines the LFA-based Cardiac Marker study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

Table of Contents

1 Study Coverage
    1.1 Introduction to LFA-based Cardiac Marker: Definition, Properties, and Key Attributes
    1.2 Market Segmentation by Type
        1.2.1 Global LFA-based Cardiac Marker Market Size by Type, 2020 VS 2024 VS 2031
        1.2.2 Troponin
        1.2.3 CK-MB
        1.2.4 Myoglobin
        1.2.5 Others
    1.3 Market Segmentation by Application
        1.3.1 Global LFA-based Cardiac Marker Market Size by Application, 2020 VS 2024 VS 2031
        1.3.2 Laboratory Testing
        1.3.3 Point-of-care Testing
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

2 Executive Summary
    2.1 Global LFA-based Cardiac Marker Revenue Estimates and Forecasts 2020-2031
    2.2 Global LFA-based Cardiac Marker Revenue by Region
        2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
        2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
        2.2.3 Global Revenue Market Share by Region (2020-2031)
        2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players
    3.1 Global LFA-based Cardiac Marker Player Revenue Rankings and Profitability
        3.1.1 Global Revenue (Value) by Players (2020-2025)
        3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
        3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
        3.1.4 Gross Margin by Top Player (2020 VS 2024)
    3.2 Global LFA-based Cardiac Marker Companies Headquarters and Service Footprint
    3.3 Main Product Type Market Size by Players
        3.3.1 Troponin Market Size by Players
        3.3.2 CK-MB Market Size by Players
        3.3.3 Myoglobin Market Size by Players
        3.3.4 Others Market Size by Players
    3.4 Global LFA-based Cardiac Marker Market Concentration and Dynamics
        3.4.1 Global Market Concentration (CR5 and HHI)
        3.4.2 Entrant/Exit Impact Analysis
        3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis
    4.1 Global LFA-based Cardiac Marker Revenue Trends by Type
        4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
        4.1.2 Global Revenue Market Share by Type (2020-2031)
    4.2 Key Product Attributes and Differentiation
    4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
        4.3.1 High-Growth Niches and Adoption Drivers
        4.3.2 Profitability Hotspots and Cost Drivers
        4.3.3 Substitution Threats

5 Global Downstream Application Analysis
    5.1 Global LFA-based Cardiac Marker Revenue by Application
        5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
        5.1.2 Revenue Market Share by Application (2020-2031)
        5.1.3 High-Growth Application Identification
        5.1.4 Emerging Application Case Studies
    5.2 Downstream Customer Analysis
        5.2.1 Top Customers by Region
        5.2.2 Top Customers by Application

6 North America
    6.1 North America Market Size (2020-2031)
    6.2 North America Key Players Revenue in 2024
    6.3 North America LFA-based Cardiac Marker Market Size by Type (2020-2031)
    6.4 North America LFA-based Cardiac Marker Market Size by Application (2020-2031)
    6.5 North America Growth Accelerators and Market Barriers
    6.6 North America LFA-based Cardiac Marker Market Size by Country
        6.6.1 North America Revenue Trends by Country
        6.6.2 US
        6.6.3 Canada
        6.6.4 Mexico

7 Europe
    7.1 Europe Market Size (2020-2031)
    7.2 Europe Key Players Revenue in 2024
    7.3 Europe LFA-based Cardiac Marker Market Size by Type (2020-2031)
    7.4 Europe LFA-based Cardiac Marker Market Size by Application (2020-2031)
    7.5 Europe Growth Accelerators and Market Barriers
    7.6 Europe LFA-based Cardiac Marker Market Size by Country
        7.6.1 Europe Revenue Trends by Country
        7.6.2 Germany
        7.6.3 France
        7.6.4 U.K.
        7.6.5 Italy
        7.6.6 Russia

8 Asia-Pacific
    8.1 Asia-Pacific Market Size (2020-2031)
    8.2 Asia-Pacific Key Players Revenue in 2024
    8.3 Asia-Pacific LFA-based Cardiac Marker Market Size by Type (2020-2031)
    8.4 Asia-Pacific LFA-based Cardiac Marker Market Size by Application (2020-2031)
    8.5 Asia-Pacific Growth Accelerators and Market Barriers
    8.6 Asia-Pacific LFA-based Cardiac Marker Market Size by Region
        8.6.1 Asia-Pacific Revenue Trends by Region
    8.7 China
    8.8 Japan
    8.9 South Korea
    8.10 Australia
    8.11 India
    8.12 Southeast Asia
        8.12.1 Indonesia
        8.12.2 Vietnam
        8.12.3 Malaysia
        8.12.4 Philippines
        8.12.5 Singapore

9 Central and South America
    9.1 Central and South America Market Size (2020-2031)
    9.2 Central and South America Key Players Revenue in 2024
    9.3 Central and South America LFA-based Cardiac Marker Market Size by Type (2020-2031)
    9.4 Central and South America LFA-based Cardiac Marker Market Size by Application (2020-2031)
    9.5 Central and South America Investment Opportunities and Key Challenges
    9.6 Central and South America LFA-based Cardiac Marker Market Size by Country
        9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
        9.6.2 Brazil
        9.6.3 Argentina

10 Middle East and Africa
    10.1 Middle East and Africa Market Size (2020-2031)
    10.2 Middle East and Africa Key Players Revenue in 2024
    10.3 Middle East and Africa LFA-based Cardiac Marker Market Size by Type (2020-2031)
    10.4 Middle East and Africa LFA-based Cardiac Marker Market Size by Application (2020-2031)
    10.5 Middle East and Africa Investment Opportunities and Key Challenges
    10.6 Middle East and Africa LFA-based Cardiac Marker Market Size by Country
        10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
        10.6.2 GCC Countries
        10.6.3 Israel
        10.6.4 Egypt
        10.6.5 South Africa

11 Corporate Profile
    11.1 Roche
        11.1.1 Roche Corporation Information
        11.1.2 Roche Business Overview
        11.1.3 Roche LFA-based Cardiac Marker Product Features and Attributes
        11.1.4 Roche LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.1.5 Roche LFA-based Cardiac Marker Revenue by Product in 2024
        11.1.6 Roche LFA-based Cardiac Marker Revenue by Application in 2024
        11.1.7 Roche LFA-based Cardiac Marker Revenue by Geographic Area in 2024
        11.1.8 Roche LFA-based Cardiac Marker SWOT Analysis
        11.1.9 Roche Recent Developments
    11.2 Abbott
        11.2.1 Abbott Corporation Information
        11.2.2 Abbott Business Overview
        11.2.3 Abbott LFA-based Cardiac Marker Product Features and Attributes
        11.2.4 Abbott LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.2.5 Abbott LFA-based Cardiac Marker Revenue by Product in 2024
        11.2.6 Abbott LFA-based Cardiac Marker Revenue by Application in 2024
        11.2.7 Abbott LFA-based Cardiac Marker Revenue by Geographic Area in 2024
        11.2.8 Abbott LFA-based Cardiac Marker SWOT Analysis
        11.2.9 Abbott Recent Developments
    11.3 Siemens
        11.3.1 Siemens Corporation Information
        11.3.2 Siemens Business Overview
        11.3.3 Siemens LFA-based Cardiac Marker Product Features and Attributes
        11.3.4 Siemens LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.3.5 Siemens LFA-based Cardiac Marker Revenue by Product in 2024
        11.3.6 Siemens LFA-based Cardiac Marker Revenue by Application in 2024
        11.3.7 Siemens LFA-based Cardiac Marker Revenue by Geographic Area in 2024
        11.3.8 Siemens LFA-based Cardiac Marker SWOT Analysis
        11.3.9 Siemens Recent Developments
    11.4 Danaher
        11.4.1 Danaher Corporation Information
        11.4.2 Danaher Business Overview
        11.4.3 Danaher LFA-based Cardiac Marker Product Features and Attributes
        11.4.4 Danaher LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.4.5 Danaher LFA-based Cardiac Marker Revenue by Product in 2024
        11.4.6 Danaher LFA-based Cardiac Marker Revenue by Application in 2024
        11.4.7 Danaher LFA-based Cardiac Marker Revenue by Geographic Area in 2024
        11.4.8 Danaher LFA-based Cardiac Marker SWOT Analysis
        11.4.9 Danaher Recent Developments
    11.5 Bio-Rad Laboratories
        11.5.1 Bio-Rad Laboratories Corporation Information
        11.5.2 Bio-Rad Laboratories Business Overview
        11.5.3 Bio-Rad Laboratories LFA-based Cardiac Marker Product Features and Attributes
        11.5.4 Bio-Rad Laboratories LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.5.5 Bio-Rad Laboratories LFA-based Cardiac Marker Revenue by Product in 2024
        11.5.6 Bio-Rad Laboratories LFA-based Cardiac Marker Revenue by Application in 2024
        11.5.7 Bio-Rad Laboratories LFA-based Cardiac Marker Revenue by Geographic Area in 2024
        11.5.8 Bio-Rad Laboratories LFA-based Cardiac Marker SWOT Analysis
        11.5.9 Bio-Rad Laboratories Recent Developments
    11.6 BioMérieux
        11.6.1 BioMérieux Corporation Information
        11.6.2 BioMérieux Business Overview
        11.6.3 BioMérieux LFA-based Cardiac Marker Product Features and Attributes
        11.6.4 BioMérieux LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.6.5 BioMérieux Recent Developments
    11.7 Thermo Fisher
        11.7.1 Thermo Fisher Corporation Information
        11.7.2 Thermo Fisher Business Overview
        11.7.3 Thermo Fisher LFA-based Cardiac Marker Product Features and Attributes
        11.7.4 Thermo Fisher LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.7.5 Thermo Fisher Recent Developments
    11.8 Ortho Clinical Diagnostics
        11.8.1 Ortho Clinical Diagnostics Corporation Information
        11.8.2 Ortho Clinical Diagnostics Business Overview
        11.8.3 Ortho Clinical Diagnostics LFA-based Cardiac Marker Product Features and Attributes
        11.8.4 Ortho Clinical Diagnostics LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.8.5 Ortho Clinical Diagnostics Recent Developments
    11.9 LSI Medience Corporation
        11.9.1 LSI Medience Corporation Corporation Information
        11.9.2 LSI Medience Corporation Business Overview
        11.9.3 LSI Medience Corporation LFA-based Cardiac Marker Product Features and Attributes
        11.9.4 LSI Medience Corporation LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.9.5 LSI Medience Corporation Recent Developments
    11.10 Randox laboratories
        11.10.1 Randox laboratories Corporation Information
        11.10.2 Randox laboratories Business Overview
        11.10.3 Randox laboratories LFA-based Cardiac Marker Product Features and Attributes
        11.10.4 Randox laboratories LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.10.5 Company Ten Recent Developments
    11.11 Wondfo Biotech
        11.11.1 Wondfo Biotech Corporation Information
        11.11.2 Wondfo Biotech Business Overview
        11.11.3 Wondfo Biotech LFA-based Cardiac Marker Product Features and Attributes
        11.11.4 Wondfo Biotech LFA-based Cardiac Marker Revenue and Gross Margin (2020-2025)
        11.11.5 Wondfo Biotech Recent Developments

12 LFA-based Cardiac MarkerIndustry Chain Analysis
    12.1 LFA-based Cardiac Marker Industry Chain
    12.2 Upstream Analysis
        12.2.1 Upstream Key Suppliers
    12.3 Middlestream Analysis
    12.4 Downstream Sales Model and Distribution Networks
        12.4.1 Sales Channels
        12.4.2 Distributors

13 LFA-based Cardiac Marker Market Dynamics
    13.1 Industry Trends and Evolution
    13.2 Market Growth Drivers and Emerging Opportunities
    13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global LFA-based Cardiac Marker Study

15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
            15.1.1.1 Research Programs/Design
            15.1.1.2 Market Size Estimation
            15.1.1.3 Market Breakdown and Data Triangulation
        15.1.2 Data Source
            15.1.2.1 Secondary Sources
            15.1.2.2 Primary Sources
    15.2 Author Details

Table of Figures

List of Tables
 Table 1. Global LFA-based Cardiac Marker Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global LFA-based Cardiac Marker Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global LFA-based Cardiac Marker Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global LFA-based Cardiac Marker Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global LFA-based Cardiac Marker Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global LFA-based Cardiac Marker Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global LFA-based Cardiac Marker Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global LFA-based Cardiac Marker by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in LFA-based Cardiac Marker as of 2024)
 Table 11. Global LFA-based Cardiac Marker Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global LFA-based Cardiac Marker Companies Headquarters
 Table 13. Global LFA-based Cardiac Marker Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global LFA-based Cardiac Marker Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global LFA-based Cardiac Marker Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global LFA-based Cardiac Marker Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global LFA-based Cardiac Marker Revenue by Application (2026-2031) & (US$ Million)
 Table 21. LFA-based Cardiac Marker High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America LFA-based Cardiac Marker Growth Accelerators and Market Barriers
 Table 25. North America LFA-based Cardiac Marker Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe LFA-based Cardiac Marker Growth Accelerators and Market Barriers
 Table 27. Europe LFA-based Cardiac Marker Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific LFA-based Cardiac Marker Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific LFA-based Cardiac Marker Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America LFA-based Cardiac Marker Investment Opportunities and Key Challenges
 Table 31. Central and South America LFA-based Cardiac Marker Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa LFA-based Cardiac Marker Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa LFA-based Cardiac Marker Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Roche Corporation Information
 Table 35. Roche Description and Major Businesses
 Table 36. Roche Product Features and Attributes
 Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Roche Revenue Proportion by Product in 2024
 Table 39. Roche Revenue Proportion by Application in 2024
 Table 40. Roche Revenue Proportion by Geographic Area in 2024
 Table 41. Roche LFA-based Cardiac Marker SWOT Analysis
 Table 42. Roche Recent Developments
 Table 43. Abbott Corporation Information
 Table 44. Abbott Description and Major Businesses
 Table 45. Abbott Product Features and Attributes
 Table 46. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Abbott Revenue Proportion by Product in 2024
 Table 48. Abbott Revenue Proportion by Application in 2024
 Table 49. Abbott Revenue Proportion by Geographic Area in 2024
 Table 50. Abbott LFA-based Cardiac Marker SWOT Analysis
 Table 51. Abbott Recent Developments
 Table 52. Siemens Corporation Information
 Table 53. Siemens Description and Major Businesses
 Table 54. Siemens Product Features and Attributes
 Table 55. Siemens Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Siemens Revenue Proportion by Product in 2024
 Table 57. Siemens Revenue Proportion by Application in 2024
 Table 58. Siemens Revenue Proportion by Geographic Area in 2024
 Table 59. Siemens LFA-based Cardiac Marker SWOT Analysis
 Table 60. Siemens Recent Developments
 Table 61. Danaher Corporation Information
 Table 62. Danaher Description and Major Businesses
 Table 63. Danaher Product Features and Attributes
 Table 64. Danaher Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Danaher Revenue Proportion by Product in 2024
 Table 66. Danaher Revenue Proportion by Application in 2024
 Table 67. Danaher Revenue Proportion by Geographic Area in 2024
 Table 68. Danaher LFA-based Cardiac Marker SWOT Analysis
 Table 69. Danaher Recent Developments
 Table 70. Bio-Rad Laboratories Corporation Information
 Table 71. Bio-Rad Laboratories Description and Major Businesses
 Table 72. Bio-Rad Laboratories Product Features and Attributes
 Table 73. Bio-Rad Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Bio-Rad Laboratories Revenue Proportion by Product in 2024
 Table 75. Bio-Rad Laboratories Revenue Proportion by Application in 2024
 Table 76. Bio-Rad Laboratories Revenue Proportion by Geographic Area in 2024
 Table 77. Bio-Rad Laboratories LFA-based Cardiac Marker SWOT Analysis
 Table 78. Bio-Rad Laboratories Recent Developments
 Table 79. BioMérieux Corporation Information
 Table 80. BioMérieux Description and Major Businesses
 Table 81. BioMérieux Product Features and Attributes
 Table 82. BioMérieux Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. BioMérieux Recent Developments
 Table 84. Thermo Fisher Corporation Information
 Table 85. Thermo Fisher Description and Major Businesses
 Table 86. Thermo Fisher Product Features and Attributes
 Table 87. Thermo Fisher Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Thermo Fisher Recent Developments
 Table 89. Ortho Clinical Diagnostics Corporation Information
 Table 90. Ortho Clinical Diagnostics Description and Major Businesses
 Table 91. Ortho Clinical Diagnostics Product Features and Attributes
 Table 92. Ortho Clinical Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Ortho Clinical Diagnostics Recent Developments
 Table 94. LSI Medience Corporation Corporation Information
 Table 95. LSI Medience Corporation Description and Major Businesses
 Table 96. LSI Medience Corporation Product Features and Attributes
 Table 97. LSI Medience Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. LSI Medience Corporation Recent Developments
 Table 99. Randox laboratories Corporation Information
 Table 100. Randox laboratories Description and Major Businesses
 Table 101. Randox laboratories Product Features and Attributes
 Table 102. Randox laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Randox laboratories Recent Developments
 Table 104. Wondfo Biotech Corporation Information
 Table 105. Wondfo Biotech Description and Major Businesses
 Table 106. Wondfo Biotech Product Features and Attributes
 Table 107. Wondfo Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Wondfo Biotech Recent Developments
 Table 109. Raw Materials Key Suppliers
 Table 110. Distributors List
 Table 111. Market Trends and Market Evolution
 Table 112. Market Drivers and Opportunities
 Table 113. Market Challenges, Risks, and Restraints
 Table 114. Research Programs/Design for This Report
 Table 115. Key Data Information from Secondary Sources
 Table 116. Key Data Information from Primary Sources


List of Figures
 Figure 1. LFA-based Cardiac Marker Product Picture
 Figure 2. Global LFA-based Cardiac Marker Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Troponin Product Picture
 Figure 4. CK-MB Product Picture
 Figure 5. Myoglobin Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global LFA-based Cardiac Marker Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Laboratory Testing
 Figure 9. Point-of-care Testing
 Figure 10. LFA-based Cardiac Marker Report Years Considered
 Figure 11. Global LFA-based Cardiac Marker Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 13. Global LFA-based Cardiac Marker Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global LFA-based Cardiac Marker Revenue Market Share by Region (2020-2031)
 Figure 15. Global LFA-based Cardiac Marker Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. Troponin Revenue Market Share by Player in 2024
 Figure 18. CK-MB Revenue Market Share by Player in 2024
 Figure 19. Myoglobin Revenue Market Share by Player in 2024
 Figure 20. Others Revenue Market Share by Player in 2024
 Figure 21. Global LFA-based Cardiac Marker Revenue Market Share by Type (2020-2031)
 Figure 22. Global LFA-based Cardiac Marker Revenue Market Share by Application (2020-2031)
 Figure 23. North America LFA-based Cardiac Marker Revenue YoY (2020-2031) & (US$ Million)
 Figure 24. North America Top 5 Players LFA-based Cardiac Marker Revenue (US$ Million) in 2024
 Figure 25. North America LFA-based Cardiac Marker Revenue (US$ Million) by Type (2020 - 2031)
 Figure 26. North America LFA-based Cardiac Marker Revenue (US$ Million) by Application (2020-2031)
 Figure 27. US LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 28. Canada LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 29. Mexico LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 30. Europe LFA-based Cardiac Marker Revenue YoY (2020-2031) & (US$ Million)
 Figure 31. Europe Top 5 Players LFA-based Cardiac Marker Revenue (US$ Million) in 2024
 Figure 32. Europe LFA-based Cardiac Marker Revenue (US$ Million) by Type (2020-2031)
 Figure 33. Europe LFA-based Cardiac Marker Revenue (US$ Million) by Application (2020-2031)
 Figure 34. Germany LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 35. France LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 36. U.K. LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 37. Italy LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 38. Russia LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific LFA-based Cardiac Marker Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Asia-Pacific Top 8 Players LFA-based Cardiac Marker Revenue (US$ Million) in 2024
 Figure 41. Asia-Pacific LFA-based Cardiac Marker Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Asia-Pacific LFA-based Cardiac Marker Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Indonesia LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 44. Japan LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 45. South Korea LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 46. Australia LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 47. India LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 48. Indonesia LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 49. Vietnam LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 50. Malaysia LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 51. Philippines LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 52. Singapore LFA-based Cardiac Marker Revenue (2020-2031) & (US$ Million)
 Figure 53. Central and South America LFA-based Cardiac Marker Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Central and South America Top 5 Players LFA-based Cardiac Marker Revenue (US$ Million) in 2024
 Figure 55. Central and South America LFA-based Cardiac Marker Revenue (US$ Million) by Type (2020-2031)
 Figure 56. Central and South America LFA-based Cardiac Marker Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Brazil LFA-based Cardiac Marker Revenue (2020-2025) & (US$ Million)
 Figure 58. Argentina LFA-based Cardiac Marker Revenue (2020-2025) & (US$ Million)
 Figure 59. Middle East and Africa LFA-based Cardiac Marker Revenue YoY (2020-2031) & (US$ Million)
 Figure 60. Middle East and Africa Top 5 Players LFA-based Cardiac Marker Revenue (US$ Million) in 2024
 Figure 61. South America LFA-based Cardiac Marker Revenue (US$ Million) by Type (2020-2031)
 Figure 62. Middle East and Africa LFA-based Cardiac Marker Revenue (US$ Million) by Application (2020-2031)
 Figure 63. GCC Countries LFA-based Cardiac Marker Revenue (2020-2025) & (US$ Million)
 Figure 64. Israel LFA-based Cardiac Marker Revenue (2020-2025) & (US$ Million)
 Figure 65. Egypt LFA-based Cardiac Marker Revenue (2020-2025) & (US$ Million)
 Figure 66. South Africa LFA-based Cardiac Marker Revenue (2020-2025) & (US$ Million)
 Figure 67. LFA-based Cardiac Marker Industry Chain Mapping
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed